Edwards Lifesciences Corp. — Q1 2024 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2024. Edwards develops and sells therapies for structural heart disease and critical care monitoring, across TAVR, transcatheter mitral and tricuspid therapies (TMTT), Surgical Structural Heart, and Critical Care. The company plans to spin off Critical Care as a separate public company near the end of 2024, subject to customary conditions and approvals.
Financial performance
- Revenue: Net sales were $1.598 billion, up 9.5% from $1.460 billion. TAVR sales rose 6.3% to $1.008 billion; TMTT rose 75.2% to $72.9 million; Surgical Structural Heart rose 7.2% to $266.1 million; and Critical Care rose 13.3% to $251.3 million.
- Profit and margins: Gross profit was $1.213 billion, up 7.3%; gross margin was approximately 75.9%, versus 77.4% a year earlier. Operating income was $387.5 million, approximately flat year over year, with operating margin of 24.2% versus 26.6%. Net income attributable to Edwards was $351.9 million, up 3.3%; diluted EPS was $0.58 versus $0.56.
- Cash flow: Operating cash flow was negative $53.5 million versus positive $314.1 million. The company attributed the decline primarily to a $305 million IRS deposit made to mitigate interest on disputed potential tax liabilities. Investing activities provided $63.1 million; capital expenditures were $65.3 million. Financing activities provided $61.7 million, mainly from stock-plan proceeds.
- Liquidity and debt: Cash and cash equivalents were $1.225 billion, with short-term investments of $473.0 million. Total current assets were $4.171 billion and current liabilities $1.111 billion. Long-term debt carrying value was $597.2 million; no borrowings were outstanding under the $750 million revolving credit facility. Stockholders’ equity totaled $7.186 billion.
- Other metrics: R&D expense was $285.2 million, or 17.8% of sales. The effective tax rate was 14.3%, compared with 14.6% a year earlier.
Material changes versus Q1 2023
- Revenue increased by $138.6 million, led by TAVR; the largest percentage growth was in TMTT, from a smaller base. Sales increased in the United States, Europe, and Rest of World, while Japan declined 2.8%.
- Gross margin fell by approximately 1.5 percentage points, with management citing a 1.6-point negative impact from foreign-exchange movements.
- SG&A and R&D expenses rose to support field personnel, growth initiatives, clinical activity, and product development. Operating income remained nearly unchanged.
- Q1 2024 included $41.3 million of separation costs for the planned Critical Care spin-off. Q1 2023 included $43.5 million of intellectual-property agreement and certain litigation expenses, including a $37.0 million charge related primarily to prior commercial sales under the Medtronic agreement.
Outlook, commentary, and risks
- Guidance: The filing text does not provide a clear numerical revenue or earnings outlook for 2024.
- Business developments: Edwards reported FDA approval of EVOQUE for tricuspid regurgitation in February 2024 and CE Mark approval for the SAPIEN 3 Ultra RESILIA valve in Europe in January. Management highlighted ongoing clinical trials and investment in aortic valve innovation.
- Spin-off: The planned Critical Care separation is expected near year-end 2024; completion depends on board approval, tax-related conditions, and an effective Form 10 registration statement. Related Q1 costs were $41.3 million.
- Tax contingencies: The IRS seeks $269.3 million of additional tax, before interest and a repatriation tax offset, for 2015–2017 transfer-pricing matters. The company is contesting the claim and made a $305 million deposit in March 2024. Related 2018–2023 matters remain under examination. The Israel Tax Authority separately assessed approximately $110 million, excluding interest and penalties, concerning an alleged 2017 intellectual-property transfer; Edwards disputes the claim. Outcomes could materially affect results, and the company says they cannot be predicted with certainty.
- Other risks: Disclosed matters include an FCPA investigation, European Commission investigation of certain business and patent practices, and patent litigation. The company says it cannot predict some outcomes or estimate certain potential losses. Foreign exchange, investment valuation, product development and adoption, competition, regulation, and supplier risks are also highlighted. Management reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Progress, cost, timing, and tax conditions for the planned Critical Care spin-off.
- Developments in the IRS transfer-pricing dispute and Israel tax assessment, including any effects on tax deposits, accruals, or cash flow.
- Whether sales growth—especially in TMTT—continues and whether foreign exchange and product mix improve or further pressure gross margin.
- Cash conversion in subsequent quarters, given negative Q1 operating cash flow and the tax deposit.
- Clinical, regulatory, and commercial progress for key products and trials, and any material outcomes from legal or governmental investigations.